Sanofi Winthrop Industrie – FDA 483
An FDA inspection of Genzyme Polyclonals SAS in Lyon, France, a drug substance manufacturer, revealed significant deficiencies across multiple areas. The firm was cited for inadequate data integrity controls, including issues with second-person review, computerized system verification, and unauthorized file manipulation. Additionally, the inspection found that the Quality Assurance unit failed to effectively investigate deviations and that environmental monitoring procedures were deficient, alongside issues with equipment design and adherence to product specifications.
- Company
- Sanofi Winthrop Industrie
- Product type
- drugs
ID · 8dbf51b4-593d-49e9-9f9f-d9b7e01f7289
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.